Diseases associated with prematurity in correlation with N-terminal pro-brain natriuretic peptide levels during the early postnatal life

What Was Tested

This observational study looks at BNP (Nesiritide).

The aim of this observational study was to investigate the influence of different typical preterm diseases on NT-proBNP serum levels in the early postnatal period of life of a preterm infant.

Why It Was Studied

NT-proBNP levels of 118 preterm infants born ≤ 31 weeks GA were determined at the first week of life, after 4 ± 1 weeks of life, and at a corrected gestational age of 36 + 2 weeks.

At a corrected gestational age of 36 ± 2 weeks, the researchers examined the effect of retinopathy of prematurity (ROP), BPD, BPD-associated PH, and late infection on NT-proBNP levels.

Who Took Part

According to the abstract, 118 infants were involved.

The age groups tagged for this paper are infants.

What Was Measured

NT-proBNP levels of 118 preterm infants born ≤ 31 weeks GA were determined at the first week of life, after 4 ± 1 weeks of life, and at a corrected gestational age of 36 + 2 weeks.

At a corrected gestational age of 36 ± 2 weeks, the researchers examined the effect of retinopathy of prematurity (ROP), BPD, BPD-associated PH, and late infection on NT-proBNP levels.

PubMed files the paper under topics including Infant, Premature, Bronchopulmonary Dysplasia, Hypertension, Pulmonary, Retinopathy of Prematurity, Biomarkers, Natriuretic Peptide, Brain and Ductus Arteriosus, Patent.

Author keywords: N-terminal pro-brain natriuretic peptide, Patent ductus arteriosus, Preterm infant and Pulmonary hypertension.

What This Means in Plain Language

This is an observational study of BNP (Nesiritide) in 118 infants.

The publication is from 2023 (European journal of pediatrics), a journal based in Germany.

More context: the BNP (Nesiritide) compound page, all human trials.